Tailored Micronization Services to Streamline Drug Development
Microsize provides Particle Size Reduction, Powder Classification and Analytical Services to a range of pharma stakeholders in need of a center of excellence for their product development and/or commercial manufacturing. Microsize has unmatched expertise in developing milling and micronization processes with a diverse range of API and excipient materials with unique physical property challenges.
High turn feasibility studies can take place within our development suites with as little as 1-5 grams of API. For highly potent compounds including cytotoxics (HPAPIs), a world-class high containment infrastructure, is available in our R&D labs and GMP suites to best match the client stage of development.
Our Customers Include:
- Small biotechs to Big Pharma
- CDMO’s (API, Dosage Form, Integrated)
- Functional Excipient Companies
Types of Molecules:
- Small Molecule APIs and HPAPIs
- Functional Excipients
- NCEs, 505b2s, Generics
Phases of Development Supported:
- Discovery
- Phases I-III
- Commercial Launch
- Generic
Our Services Pipeline
FAQs
Q: What is included in Microsize’s contract services?
A: Our contract services include particle size reduction, powder classification, analytical characterization, and full-scale micronization support for complex APIs and excipients.
Q: How does Microsize scale projects quickly?
A: Our three FDA-inspected facilities enable flexible, high-volume production so projects can move efficiently from early development through clinical and commercial micronization without changing partners.
Q: Can Microsize handle high-potency APIs (HPAPIs)?
A: Yes. We use hard-wall and single-use containment technologies for safe, precise handling of HPAPIs.
Q: How does Microsize support fast drug development timelines?
A: By combining high-touch client service, direct access to technical experts, and streamlined internal processes, we cut decision and changeover times while maintaining reliability and compliance.